“We are very excited to announce our first commercial shipment of FLEXMAP 3D,” said Douglas Bryant, Executive Vice President and Chief Operating Officer of Luminex. “The increased speed, increased multiplexing capabilities, as well as the improved workflow of the instrument will offer researchers and clinicians rapid and accurate results to improve the health and well-being of people around the world.”
The robust FLEXMAP 3D system will offer medium and high volume laboratories improved analytical performance, greater speed, front end automation, enhanced throughput and higher multiplexing capabilities. The FLEXMAP 3D system measures up to 500 analytes in a single well, as compared to the company’s current Luminex 200 system, which measures 100 analytes per well. Powered by xPONENT® 4.0 software, the system’s intuitive interface will benefit users with ease of use and a simplified and optimized workflow.
The FLEXMAP 3D system utilizes Luminex’s flexible xMAP® Technology, which is built on the existing, proven technology of flow cytometry, microspheres, lasers, digital signal processing and traditional chemistry. xMAP Technology is unique in providing both protein and nucleic acid applications on one platform, and has allowed Luminex to expand its reach into market segments such as life science research, molecular diagnostics, HLA testing, and markets as diverse as biodefense, animal health and agro-biotech.
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company’s xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company’s xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.
